Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.

Abstract

Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice. There are many regimens used to prevent HFS. However, the most effective preventive regimen has not yet been identified. Thus, we conducted a network meta-analysis to investigate the best preventive regimen for HFS. The PRISMA-NMA guidelines were used in this study. The PubMed, Cochrane, and Embase databases were searched. The main endpoint was set as HFS of National Cancer Institute grade 2 or more. We included only randomized control trials. The P-score was used to rank the regimens. Among all the regimens, topical silymarin had the best preventive ability compared with the placebo (OR: 0.08; 95% CI: 0.01-0.71). The other identified effective regimen included pyridoxine (400 mg) and celecoxib; compared with the placebo, the odds ratio was 0.27 (95% CI: 0.08-0.91) and 0.41 (95% CI: 0.18-0.95), respectively. Topical silymarin is the most useful regimen for preventing capecitabine-induced HFS.

• Authors: Yung-Shuo Kao, Chen-Hsu Lo, Yu-Kang Tu, Cheng-Hsien Hung
• Journal: Dermatologic therapy (Dermatol Ther) Vol. 35 Issue 10 Pg. e15774 (10 2022) ISSN: 1529-8019 [Electronic] United States
• PMID: 36054263 (Publication Type: Journal Article, Meta-Analysis)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Antimetabolites, Antineoplastic
• Silymarin
• Capecitabine
• Celecoxib
• Pyridoxine

Topics

• Antimetabolites, Antineoplastic (adverse effects)
• Capecitabine (adverse effects)
• Celecoxib
• Hand-Foot Syndrome (drug therapy, etiology, prevention & control)
• Humans
• Network Meta-Analysis
• Pyridoxine (therapeutic use)
• Randomized Controlled Trials as Topic
• Silymarin